title: (-)-Nyasol (cis-hinokiresinol), a norneolignan from the rhizomes of Anemarrhena asphodeloides, is a broad spectrum inhibitor of eicosanoid and nitric oxide production.
abstract: To assess the anti-inflammatory activity of constituents from the rhizomes of Anemarrhena asphodeloides, (-)-nyasol {cis-hinokiresinol, 4,4-[1Z,3R]-3-ethenyl-1-propene-1,3-diyl]bisphenol} was isolated and its anti-inflammatory activity was examined in lipopolysaccharide (LPS)-treated RAW 264.7 cells and A23187-treated RBL-1 cells. In vivo activity was measured using carrageenan-induced paw edema assay. At > 1 microM, (-)-nyasol significantly inhibited cyclooxygenase-2 (COX-2)-mediated PGE2 production and inducible nitric oxide synthase (iNOS)-mediated NO production in LPS-treated RAW 264.7 cells, a mouse macrophage-like cell line, but did not affect the expression levels of COX-2 and iNOS. (-)-Nyasol also inhibited 5-lipoxygenase (5-LOX)-mediated leukotriene production in A23187-treated RBL-1 cells. Furthermore, (-)-nyasol potently inhibited carrageenan-induced paw edema in mice (28.6-77.1% inhibition at 24-120 mg/kg). Therefore, (-)-nyasol is a potential new lead compound and may contribute to the anti-inflammatory action of A. asphodeloides, possibly by inhibiting COX-2, iNOS and 5-LOX.
authors.affiliation: College of Pharmacy, Kangwon National University, Chunchon 200-701, Korea.
authors.forename: Hyun
authors.initials: H
authors.lastname: Lim
authors.forename: Joo Won
authors.initials: JW
authors.lastname: Nam
authors.forename: Eun-Kyoung
authors.initials: EK
authors.lastname: Seo
authors.forename: Yeong Shik
authors.initials: YS
authors.lastname: Kim
authors.forename: Hyun Pyo
authors.initials: HP
authors.lastname: Kim
mesh_terms: D031403:Anemarrhena / Q000737:chemistry*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D051546:Cyclooxygenase 2 / Q000187:drug effects / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015777:Eicosanoids / Q000096:biosynthesis; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D017705:Lignans / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D008070:Lipopolysaccharides; D016859:Lipoxygenase Inhibitors; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D010636:Phenols / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D051381:Rats; D027343:Rhizome
chemical_list: D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D015777:Eicosanoids; D017705:Lignans; D008070:Lipopolysaccharides; D016859:Lipoxygenase Inhibitors; D010636:Phenols; D009569:Nitric Oxide; C109393:nyasol; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2